Document Detail


High-density lipoprotein inhibits the uptake of modified low- density lipoprotein and the expression of CD36 and FcgammaRI.
MedLine Citation:
PMID:  20467189     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Modified low-density lipoprotein (mLDL), mainly upon oxidative and enzymatic modification, is the major atherogenic lipoprotein. Conversely, high-density lipoprotein (HDL) is considered antiatherogenic because of its ability to remove cholesterol. The aim of this work was to analyze both the influence of HDL on the uptake of mLDL and the expression of CD36 and Fcgamma I receptors on monocytic cell lines during cell differentiation.
METHODS: Uptake of fluorescein isothiocyanate (FITC)-conjugated LDL and FITC-conjugated mLDL, i.e., copper-oxidized LDL (oxLDL) or trypsin enzyme modified LDL (enzLDL), was analyzed, as well as the expression of CD36 and FcgammaRI in THP-1 and U937 cells, using flow cytometry.
RESULTS: HDL inhibited the uptake of mLDL, which varied in degree depending on the cell line or type of mLDL. Further, HDL rapidly decreased CD36 and FcgammaRI involved in the uptake of mLDL.
CONCLUSIONS: We demonstrate that modified LDL promotes specific LDL receptor-independent uptake by monocytic cell lines, and that the uptake of LDL and enzLDL is less than that of oxLDL. In this process, HDL diminishes the uptake of LDL or mLDL, which may involve the down-regulation of receptors (CD36 and Fcgamma I). This regulatory process represents another way by which HDL can be anti-atherogenic and it depends on the type of modification of LDL and the stage of differentiation of monocytes to macrophages.
Authors:
Márcia Dias Teixeira Carvalho; Célia Maria Vieira Vendrame; Daniel Francisco Jacon Ketelhuth; Edite Hatsumi Yamashiro-Kanashiro; Hiro Goto; Magnus Gidlund
Related Documents :
19748619 - Contribution of apolipoprotein e genotype and docosahexaenoic acid to the ldl-cholester...
215869 - Low density lipoprotein metabolism in type iv and type v hyperlipoproteinemia.
15172629 - Clinical applications of long-term ldl-apheresis on and beyond refractory hypercholeste...
8653899 - Variability in cholesterol measurements: comparison of calculated and direct ldl choles...
219029 - Studies on the structure of low density lipoproteins isolated from macaca fascicularis ...
15242239 - A new approach to the quantitative measurement of dense ldl subfractions.
1117239 - Effect of calcium deprivation on parathyroid hormone-mediated bone and kidney contribut...
11514379 - Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits...
8298999 - Neuropeptide y projection from arcuate nucleus to parvocellular division of paraventric...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-05-13
Journal Detail:
Title:  Journal of atherosclerosis and thrombosis     Volume:  17     ISSN:  1880-3873     ISO Abbreviation:  J. Atheroscler. Thromb.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-09-06     Completed Date:  2011-01-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9506298     Medline TA:  J Atheroscler Thromb     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  844-57     Citation Subset:  IM    
Affiliation:
Laboratório de Imunofisiopatologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. mdias@usp.br
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, CD36 / metabolism*
Cells, Cultured
Humans
Immunoblotting
Lipoproteins, HDL / pharmacology*
Lipoproteins, LDL / metabolism*
Monocytes / drug effects*,  metabolism
Receptors, IgG / metabolism*
Receptors, Lipoprotein / metabolism
Receptors, Scavenger / metabolism
Thiobarbituric Acid Reactive Substances / pharmacology
Chemical
Reg. No./Substance:
0/Antigens, CD36; 0/FCGR1A protein, human; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Receptors, IgG; 0/Receptors, Lipoprotein; 0/Receptors, Scavenger; 0/Thiobarbituric Acid Reactive Substances; 0/oxidized low density lipoprotein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pioglitazone Decreases Plasma Angiotensin II Concentration inType 2 Diabetes.
Next Document:  Significance of serum high-density lipoprotein cholesterol levels for diagnosis of coronary stenosis...